病理的心室改造:メカニズム: 2 の 2 の 1 部
Jana S Burchfield1, Min Xie, Joseph A Hill
1Texas Heart Institute, Houston, TX, USA.
Circulation
|July 24, 2013
まとめ
高い心不全再入院率は,新しい治療法を必要とする. このレビューでは,新しい治療法の開発に不可欠な,病理的な左心室リモデリングの複雑な分子および細胞メカニズムを調べています.
科学分野:
- 心血管研究 循環器科の研究
- 分子生物学は分子生物学である.
- 病理生理学 病理生理学とは
背景:
- 進歩にもかかわらず,心不全の再入院は依然として重要な臨床的課題です.
- 現在の治療法は,高い罹病率と死亡率を完全に解決していない.
- 新しい治療戦略と医療機器の緊急の必要性が存在します.
研究 の 目的:
- 心不全における病理的左心室改造の基礎となる分子および細胞メカニズムを見直す.
- さまざまな改造プロセスの相互接続性を強調する.
- より効果的な心不全治療法の開発を促す.
主な方法:
- 分子および細胞のメカニズムに関する文献レビュー.
- 心臓の改造における相互に関連したプロセスの分析.
- 病理的心室改造に関する現在の理解の統合.
主要な成果:
- 左心室の改造は,筋細胞の変化,血管稀縮,線維症,炎症,電気生理学的変化を含む複雑で相互に関連したプロセスを含む.
- 単一の経路をターゲットにすることは,これらのイベントの相互に関連した性質のために不十分かもしれません.
- これらのメカニズムを理解することは,心不全の進行に対処するための鍵です.
結論:
- 病理的左心室リモデリングは,包括的な治療アプローチを必要とする多面的なプロセスです.
- 新しい治療法は,分子および細胞の相互作用を考慮する必要があります.
- これらのメカニズムに関するさらなる研究は,心不全管理におけるイノベーションを推進します.
関連する概念動画
Pathophysiology of Heart Failure
4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Mitral Valve Prolapse I: Introduction
1.1K
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
1.1K
Mitral Regurgitation I: Introduction
1.3K
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1.3K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790


